Skip to main content

Table 3 Costs related to T2DM (€ 2021)

From: Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

Parameter

Cost

Distribution

Reference

First year

Maintenance

Fatal event

Non-fatal event

Micro-and macrovascular complications

 Unstable angina

€ 4557

€ 3090

€ 892

Gamma

[24, 25]

 Myocardial infarction

€ 10464

€ 7036

€ 892

Gamma

[24, 25]

 Heart failure

€ 4222

€ 3259

€ 3683

Gamma

[24, 25]

 Stroke

€ 6 660

€ 4738

€ 3725

Gamma

[24, 25]

 End-stage kidney disease

€ 53310

€ 53310

€ 28931

Gamma

[27, 28]

 Blindness

-

€ 2275

€ 834

Gamma

[24, 25]

 Ulcers

-

€ 5163

€ 402

Gamma

[24, 26]

 

Cost

 

Reference

Pharmacological treatment

 Dapagliflozin

€ 624.37

Gamma

[22]

Adverse events

 Urinary tract infection

€ 53

Gamma

[22, 29]

 Genital tract infection

€ 53

Gamma

[22, 29]

 Diabetic ketoacidosis

€ 3942

Gamma

[24]

 Acute kidney failure

€ 4151

Gamma

[24]

 Fractures

€ 4341

Gamma

[29]

Hypoglycemic events

 Severe hypoglycemia

€ 696

Gamma

[30]

 Treatment discontinuation

€ 52

Gamma

[29]

Chronic kidney disease

 Stage 2

€ 1304

Gamma

[31]

 Stage 3

€ 4860

Gamma

[32]

 Stage 4

€ 8058

Gamma

[33]

 Stage 5

€ 13659

Gamma

[33]